Galmed Pharma (GLMD) Tops Q3 EPS by 19c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of $0.05, $0.19 better than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Change in Nonfarm Payrolls (Aug) 162K vs 55K Expected, Unemployment Rate 4.1%
• UBS Reiterates Buy Rating on Linde (LIN) as Challenges in Helium Are 'Being Managed'